The global botulinum toxin CDMO market size was estimated at USD 2.5 billion in 2025 and is projected to reach USD 5.8 billion by 2033, growing at a CAGR of 11.5% from 2026 to 2033. The market is experiencing significant momentum as pharmaceutical and biotechnology companies increasingly rely on contract development and manufacturing organizations (CDMOs) to streamline production, enhance...